Bristol-Myers Squibb Company

NYSE: BMY
$55.83
-$0.98 (-1.7%)
Closing Price on January 10, 2025

BMY Articles

The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes...
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest decreased.
The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Wednesday's top analyst upgrades, downgrades and initiations include Athenhealth, AT&T, Cepheid, Chevron, Dollar General and Mobileye.
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and added some color.
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.